Study of Oxaliplatin Plus Bevacizumab in Germ Cell Tumor Patients
Part of paid clinical trials in Indianapolis, Indiana.
- Sponsor
- Indiana University
- Study ID
- NCT00393861
- Phase
- PHASE2
- Status
- Completed
Conditions
- Neoplasms, Germ Cell and Embryonal
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Bevacizumab and Oxaliplatin — DRUGOxaliplatin 85 mg/M2 IV over 2 hours plus Bevacizumab 10 mg/kg IV over 90 minutes
Study Details
The purpose of this study is to evaluate the effectiveness of oxaliplatin and bevacizumab in patients with refractory or relapsed germ cell tumors.
Key Dates
- First listed
- Oct 30, 2006
- Start date
- Oct 31, 2006
- Status verified
- Feb 2016
- Primary completion
- Oct 31, 2012
- Completion
- Nov 30, 2014
Study Design
- Enrollment
- 29 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: oxaliplatin & bevacizumab
Primary Outcome Measure
Twelve Month Disease-free Survival Rate [ Time Frame: 12 month post completion of treatment ]
Locations (2)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Indiana Univeristy Cancer Center | Indianapolis | Indiana | 46202 | - |
| University of Pennsylvania:Abramson Cancer Center | Philadelphia | Pennsylvania | 19104 | - |
Find similar trials in Indianapolis, IN
Related Studies
- HSV G207 in Children With Recurrent or Refractory Cerebellar Brain TumorsPHASE1 · Recruiting · M.D. Anderson Cancer Center · Birmingham, Alabama